A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers
Status:
Completed
Trial end date:
2012-02-15
Target enrollment:
Participant gender:
Summary
GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of
antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive
including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens
associated with respiratory tract, skin and soft tissue infections including isolates
resistant to existing classes of antimicrobials. This is a First Time in Human (FTIH) study
to assess the safety, tolerability, and pharmacokinetics of single oral doses of GSK2140944
in healthy volunteers. This study will be a single-blind, randomized, placebo-controlled,
dose-rising study in healthy subjects. The proposed single doses will range from 100 mg to
3000 mg.